跳至主要内容
临床试验/NCT04304105
NCT04304105已完成不适用

Natural Progression of High-Risk Chronic Limb-Threatening Ischemia: The CLariTI Study

LimFlow, Inc.25 个研究点 分布在 2 个国家目标入组 192 人开始时间: 2020年2月24日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
LimFlow, Inc.
入组人数
192
试验地点
25
主要终点
Amputation Free Survival (AFS)

研究概览

简要总结

The objective of this observational registry is to track the clinical progression of chronic limb-threatening ischemia (CLTI) and incidence of death, amputation, and revascularization attempts over a one-year period.

详细描述

The objective of this observational registry is to track the clinical progression of chronic limb-threatening ischemia (CLTI) and incidence of death, amputation, and revascularization attempts over a one-year period.

The study population is comprised of Rutherford 5 and 6 CLTI subjects who have hemodynamic evidence of severely diminished arterial inflow of a peripheral limb and:

  1. 2 revascularizations in the last 6 months that failed to resolve symptoms, OR
  2. have inadequate popliteal, tibial, or pedal revascularization target

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Subject must be ≥18 years of age
  • Subject is Rutherford 5 or 6 classification with hemodynamic evidence of severely diminished arterial inflow of a peripheral limb and: a) 2 revascularizations in the last 6 months that failed to resolve symptoms, OR b) An inadequate popliteal, tibial, or pedal revascularization target
  • Subject is willing and able to sign the informed consent form and willing to participate in the phone follow-ups.

排除标准

  • Any significant concurrent psychological or social condition (e.g., no support person/network), which may significantly interfere with the subject's optimal participation in the study, in the opinion of the investigator.
  • Subject is participating in the PROMISE II Clinical Trial.

结局指标

主要结局

Amputation Free Survival (AFS)

时间窗: 12 months

Defined as freedom from major (above ankle) amputation and death

次要结局

  • Minor Amputation(12 months)
  • Change in Rutherford Classification(6 months and 12 months)

研究者

发起方
LimFlow, Inc.
申办方类型
Industry
责任方
Sponsor

研究点 (25)

Loading locations...

相似试验

Natural Progression of High-Risk Chronic... | 临床试验